MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biomarkers

Immunotherapy in Malignant Pleural Mesothelioma.

Frontiers in Oncology 2020 February 21 [Link] de Gooijer CJ, Borm FJ, Scherpereel A, Baas P Abstract The only registered systemic treatment for malignant pleural mesothelioma (MPM) is platinum based chemotherapy combined with pemetrexed, with or without bevacizumab. Immunotherapy did seem active in small phase II trials. In this review, we will highlight the most […]

Comments Off on Immunotherapy in Malignant Pleural Mesothelioma.

Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Journal of Immunotherapy for Cancer 2020 February [Link] Hotta K, Fujimoto N Abstract Platinum-based chemotherapy is commonly used as the standard first-line treatment for unresectable malignant pleural mesothelioma (MPM). However, in recent times, immune-checkpoint inhibitors (ICIs) have led to a paradigm shift. Herein, we review relevant literature and ongoing trials of ICIs used as both […]

Comments Off on Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.

Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.

International Journal of Environmental Research and Public Health 2020 February 10 [Link] Töreyin ZN, Ghosh M, Göksel Ö, Göksel T, Godderis L Abstract Malignant pleural mesothelioma (MPM) is mainly related to previous asbestos exposure. There is still dearth of information on non-invasive biomarkers to detect MPM at early stages. Human studies on exhaled breath biomarkers […]

Comments Off on Exhaled Breath Analysis in Diagnosis of Malignant Pleural Mesothelioma: Systematic Review.

Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.

Cancers 2020 February 7 [Link]

Comments Off on Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.

LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.

Biomarker Research 2020 January 8 [Link] Kim MK, Kim HW, Jang M, Oh SS, Yong SJ, Jeong Y, Jung SH, Choi JW Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that develops in the pleural and outer layer of tissues surrounding the lungs. MPM is primarily caused by occupational exposure to […]

Comments Off on LOX family and ZFPM2 as novel diagnostic biomarkers for malignant pleural mesothelioma.

Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.

Lung Cancer 2019 November 18 [Link] Stockhammer P, Ploenes T, Theegarten D, Schuler M, Maier S, Aigner C, Hegedus B Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is an aggressive malignancy with dismal prognosis but variable course of disease. To support diagnosis and to risk stratify patients, more reliable biomarkers are warranted. Emerging evidence underlines a […]

Comments Off on Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.

Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

Clinical Lung Cancer 2019 October 25 [Link] Paajanen J, Ilonen I, Lauri H, Järvinen T, Sutinen E, Ollila H, Rouvinen E, Lemström K, Räsänen J, Ritvos O, Koli K, Myllärniemi M Abstract BACKGROUND: Previous preclinical studies have shown that activin A is overexpressed in malignant pleural mesothelioma (MPM), associates with cancer cachexia, and is observed […]

Comments Off on Elevated Circulating Activin A Levels in Patients With Malignant Pleural Mesothelioma Are Related to Cancer Cachexia and Reduced Response to Platinum-based Chemotherapy.

The value of BAP1 expression and CDKN2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.

Cytopathology 2019 November 12 [Link] LThakfi W, Gazzo S, Blanchet M, Isaac S, Piaton E, Villeneuve L, Glehen O, Gilly FN, Brevet M Abstract OBJECTIVE: Diffuse malignant peritoneal mesothelioma (DMPM), represents 30% of all malignant mesothelioma, and is characterized by a difficult diagnosis and different presentations. Immunohistochemistry has improved the diagnostic sensitivity and specificity in […]

Comments Off on The value of BAP1 expression and CDKN2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.

Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Frontiers in Cell and Developmental Biology 2019 October 1 [Link] Johnson TG, Schelch K, Mehta S, Burgess A, Reid G Abstract Lung cancers and malignant pleural mesothelioma (MPM) have some of the worst 5-year survival rates of all cancer types, primarily due to a lack of effective treatment options for most patients. Targeted therapies have […]

Comments Off on Why Be One Protein When You Can Affect Many? The Multiple Roles of YB-1 in Lung Cancer and Mesothelioma.

Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?

Biotechnic & Histochemistry 2019 October 1 [Link] Kocaman N, Artaş G Abstract Malignant mesothelioma (MM) is a rare tumor of serous surfaces that has a poor prognosis. Cancer is a multistage process by which cells undergo metabolic and behavioral changes that cause excessive and untimely proliferation. Asprosin (ASP) and meteorin-like (METRNL) are two peptides associated […]

Comments Off on Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?